Design Template
17-18 November 2014 | Marriott Grosvenor

The future is arriving fast for the life science industry. Convergence is happening along the entirety of the industry value chain, blurring the boundaries between pharma, biotech, generics, devices and broader healthcare companies. 

Advanced technologies and materials, once the realm of science fiction, are now starting to emerge and can be expected to play a much greater role in the research efforts of life science companies in the future. Emerging market companies are expanding and edging their way to the top table as innovator drug companies. 

What will the life science company of the future look like? How will the industry be transformed?

If you missed 2014's event a snapshot of the two-days can be viewed below:


Joseph Jimenez
Chief Executive Officer 

Stefan Oschmann
Member of the Executive Board, CEO Pharma 

Michael Doherty
Global Head, Pharma Regulatory Affairs
Hoffmann La- Roche

Bahija Jallal
Executive Vice President, AstraZeneca
Head, MedImmune

Christian Hogg
Executive Director and Chief Executive Officer 
Hutchison China MedTech Limited

Dr Flemming Ornskov
Chief Executive Officer

Simon Stevens
Chief Executive Officer
NHS England

Brent Saunders
President and CEO

Watch the full On Demand video
sessions taken at 2014's event

The FT Global Pharmaceutical and Biotechnology conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives, 'feel the pulse' of the industry, and network with peers across the sector.

Thank you to everyone that joined us at 2014's event. A number of presentations we saw on the day are available to view here: